false
0001725430
0001725430
2026-02-25
2026-02-25
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date
of Report (Date of Earliest Event Reported): February 25, 2026
INTELLIGENT
BIO SOLUTIONS INC.
(Exact
name of registrant as specified in its charter)
| Delaware |
|
001-39825 |
|
82-1512711 |
(State
of
Incorporation) |
|
(Commission
File
Number) |
|
(IRS
employer
identification
no.) |
135
West, 41st Street, 5th Floor
New
York, NY 10036
(Address
of principal executive offices, including zip code)
Registrant’s
telephone number, including area code: (646) 828-8258
N/A
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
| ☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
| Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
| Common
Stock, $0.01 par value |
|
INBS |
|
The
Nasdaq Stock Market LLC |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405)
or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item
7.01 Regulation FD Disclosure.
On
February 25, 2026, Intelligent Bio Solutions Inc. (the “Company”), issued a press release (the “Press Release”)
announcing the successful receipt and deployment of the first shipment of Intelligent Fingerprinting Drug Screening Readers manufactured
under its new strategic manufacturing partnership with Syrma Johari MedTech Ltd. A copy of the press release is furnished as Exhibit
99.1 to this Current Report on Form 8-K. The foregoing disclosure is qualified in its entirety by the full text of the Press Release.
The
information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed
to be “filed” for the purpose of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor
shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended,
unless specifically identified therein as being incorporated by reference.
Item
9.01 Financial Statements and Exhibits.
| No. |
|
Description |
| 99.1 |
|
Press release dated February 25, 2026 |
| 104 |
|
Cover Page Interactive
Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
| Date: February 25, 2026 |
|
|
| |
INTELLIGENT
BIO SOLUTIONS INC. |
| |
|
|
| |
By: |
/s/ Spiro
Sakiris |
| |
Name: |
Spiro Sakiris |
| |
Title: |
Chief Financial Officer |
Exhibit 99.1
Intelligent
Bio Solutions Successfully Manufactures and Ships First Readers with New Partner, Accelerating Scale and Driving Gross Margin Expansion
in Anticipation of Planned U.S. Entry
Successful
delivery in partnership with Syrma Johari validates manufacturing scale, strengthens commercial readiness, and supports planned U.S.
market entry in 2026
Partnership
on track to deliver annual production cost savings of more than 40% with expected improvement of approximately 20 percentage points in
gross margin annually
Doubled
in-house lateral flow test strip production capacity strengthens vertical integration, accelerates R&D, and enables panel expansion
NEW
YORK, February 25, 2026 – Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”),
a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the successful receipt
and deployment of the first shipment of Intelligent Fingerprinting Drug Screening Readers manufactured under its new strategic
manufacturing partnership with Syrma Johari MedTech Ltd. (“Syrma Johari”). The shipment marks a significant step in
scaling the Company’s production capacity and validates the operational and financial benefits of the collaboration announced
in December 2025.
The
readers are now being deployed across key customer verticals, including construction, transportation and logistics, and manufacturing,
throughout the U.K. and Europe, supporting growing commercial demand and expanding the Company’s installed base ahead of planned
entry into the U.S. market, beyond the Forensic Use Only category, later this year.
The
successful first reader shipment confirms that the Syrma Johari partnership is performing as planned, with readers meeting INBS’
quality standards and manufactured in compliance with ISO 13485, MDSAP, and applicable regulatory requirements. With access to manufacturing
capacity approximately four times its prior capability, the Company is now positioned to accelerate fulfillment and is on track to deliver
annual production cost savings of more than 40%, translating to an expected improvement of approximately 20 percentage points in gross
margin annually.
In
addition to scaled reader production, INBS has considerably enhanced its manufacturing capabilities for the lateral flow test strip integral
to its testing system. The Company has sourced advanced lateral flow manufacturing equipment that has doubled its in-house production
capacity, delivering multiple strategic advantages including greater control over critical components that improve margins and reduce
lead times, increased cartridge output that provides the product development team with expanded testing inventory for faster innovation
cycles, and the ability to produce cartridges with additional test lines that unlock opportunities to explore
expanded drug panels tailored to specific customer segments, regulatory markets, or emerging substance trends.
“Receiving
and deploying our first shipment of readers from Syrma Johari, combined with doubling our in-house lateral flow test strip production
capacity, is a transformational step in our ability to scale intelligently and profitably,” said Callistus Sequeira, Vice
President of Global Quality & Operations at Intelligent Bio Solutions. “We are building a vertically integrated, cost-efficient
manufacturing engine that supports margin expansion, accelerates innovation, and positions us to enter the U.S. market with operational
strength and the capacity to grow with demand.”
The
Company expects additional production shipments throughout 2026 as it continues to build inventory, expand its commercial footprint,
and execute on its U.S. regulatory and go-to-market strategy.
About
Intelligent Bio Solutions Inc.
Intelligent
Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company delivering intelligent, rapid, non-invasive testing solutions. The
Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint
sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system,
the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis.
With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical
industries. The Company’s current customer segments outside the U.S. include construction, manufacturing and engineering, transport
and logistics firms, mining, drug treatment organizations, and coroners.
For
more information, visit: https://ibs.inc/
Forward-Looking
Statements
Some
of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section
21E of the Securities Exchange Act of 1934, and the Private Securities Litigation Reform Act of 1995, and involve risks and uncertainties.
Forward-looking statements in this press release include, without limitation, statements regarding Intelligent Bio Solutions Inc.’s
ability to successfully develop and commercialize its drug and diagnostic tests, realize commercial benefits from its partnerships and
collaborations, and secure regulatory clearance or approvals, among others. Although Intelligent Bio Solutions Inc. believes that the
expectations reflected in such forward-looking statements are reasonable as of the date made, actual results may differ materially from
those expressed or implied by such statements. Intelligent Bio Solutions Inc. has attempted to identify forward-looking statements by
terminology, including “believes,” “estimates,” “anticipates,” “expects,” “plans,”
“projects,” “intends,” “potential,” “may,” “could,” “might,”
“will,” “should,” and “approximately,” or other words that convey uncertainty of future events or
outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties,
and other factors, including those described in Intelligent Bio Solutions’ public filings with the U.S. Securities and Exchange
Commission. Any forward-looking statements contained in this release speak only as of the date of this release. Intelligent Bio Solutions
undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring
after its date or to reflect the occurrence of unanticipated events.
Company
Contact
Intelligent Bio Solutions Inc.
info@ibs.inc
Investor &
Media Contact
Valter
Pinto, Managing Director
KCSA Strategic Communications
PH: (212) 896-1254
INBS@kcsa.com
